Colossal Biosciences Raises $200 Million in Funding

Colossal Biosciences, a Dallas-based startup focused on de-extinction, has achieved a valuation of $10.2 billion following a $200 million Series C funding round led by TWG Global. This milestone makes Colossal the first startup in Texas to reach 'decacorn' status, reflecting its significant growth since its launch in September 2021. The company plans to utilize the new funding to enhance its genetic engineering technologies, further its de-extinction projects, including the woolly mammoth and dodo bird, and expand its team and lab facilities. CEO Ben Lamm emphasized the funding's role in supporting their mission to combat extinction and explore applications in conservation and healthcare. Colossal has now raised a total of $435 million since its inception, underlining its appeal to the investor community interested in innovative biotech solutions. With its ambitious goals, Colossal aims to merge science fiction with reality by reviving extinct species and restoring biodiversity.